A structured framework for evaluating CLIA-certified labs—covering regulatory compliance, payer contracts, equipment condition, and revenue cycle quality before you close.
Find Lab & Diagnostics Company Acquisition TargetsAcquiring an independent clinical laboratory requires deep scrutiny across regulatory standing, reimbursement sustainability, and operational infrastructure. With PAMA-driven Medicare rate cuts reshaping margins and accreditation requirements creating transition complexity, buyers must validate compliance, revenue quality, and key-person dependencies before committing capital.
Verify the lab's CLIA certification, CAP accreditation, state licensure, and OIG compliance history before advancing. Regulatory gaps can halt a deal or trigger post-close liability.
Confirm current CLIA certificate category, last inspection results, and CAP accreditation cycle. Identify any citations, corrective actions, or pending renewals that could lapse during ownership transfer.
Search OIG exclusion databases for the lab, owners, and medical director. Request documentation of any prior CMS audits, RAC reviews, billing settlements, or open government investigations.
Verify state laboratory licenses are current and transferable. Review referring physician arrangements for compliance with Stark Law and Anti-Kickback Statute requirements on specimen referrals.
Assess three years of accrual-based financials, payer contract terms, and billing operations to validate EBITDA sustainability and identify reimbursement exposure before valuation is finalized.
Analyze all payer agreements for reimbursement rates by CPT code, renewal dates, change-of-ownership assignment clauses, and exposure to PAMA-driven CLFS rate reductions on high-volume routine tests.
Evaluate denial rates, days sales outstanding, collection ratios, and coding accuracy. High denial rates or DSO above 60 days signal billing dysfunction that will compress post-acquisition cash flow.
Map revenue breakdown by Medicare, Medicaid, commercial payers, and self-pay. Flag tests subject to steep PAMA cuts and identify whether specialty or esoteric assays offset routine test margin pressure.
Evaluate equipment condition, referral source concentration, and personnel dependencies to quantify post-close operational risk and inform escrow, earnout, or seller financing terms.
Inventory all analyzers and instrumentation with purchase dates, maintenance logs, lease terms, and estimated remaining useful life. Quantify immediate capex needs and factor into purchase price negotiations.
Assess whether the lab director holds CLIA-required qualifications and whether their departure would trigger regulatory non-compliance. Confirm employment agreements and transition incentive structures are in place.
Request a referring provider report showing specimen volume by account and tenure. Flag any single referral source exceeding 30–40% of total volume as a concentration risk requiring earnout or escrow protection.
CLIA certificates are not automatically transferable. A change of ownership typically requires the new owner to apply for a new CLIA certificate before operating. Engage a compliance attorney early to avoid gaps that could halt operations post-close.
PAMA-driven CLFS rate reductions compress margins on high-volume routine tests, lowering sustainable EBITDA. Buyers should recast financials using current and projected CLFS rates to avoid overpaying based on historical revenue that will not recur.
Yes. CLIA-certified labs are eligible for SBA 7(a) financing. Lenders will scrutinize payer contract transferability, compliance history, and revenue sustainability, so clean financials and regulatory documentation are essential for loan approval.
An earnout tied to volume retention from top referring accounts, combined with seller financing and an escrow holdback linked to payer contract assignment milestones, aligns seller incentives and protects buyers from revenue deterioration after close.
More Lab & Diagnostics Company Guides
DealFlow OS surfaces targets with seller signals and motivation scores — so you know before you start diligence. Free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers